MP10-11 PELVIC EXTRANODAL EXTENSION LEADS TO WORSE OUTCOMES IN PENILE CANCER PATIENTS WITH POSITIVE PELVIC LYMPH NODES AND IS ASSOCIATED WITH A SURVIVAL BENEFIT AFTER ADJUVANT CHEMOTHERAPY: A MULTI-INSTITUTIONAL STUDY

Pranav Sharma,Rosa Djajadiningrat,Kamran Zargar-Shoshtari,Mario Catanzaro,Yao Zhu,Nicola Nicolai,Simon Horenblas,Philippe Spiess

DOI: https://doi.org/10.1016/j.juro.2015.02.412

2015-01-01

Abstract:You have accessJournal of UrologySexual Function/Dysfunction/Andrology: Penis/Testis/Urethra: Malignant Disease1 Apr 2015MP10-11 PELVIC EXTRANODAL EXTENSION LEADS TO WORSE OUTCOMES IN PENILE CANCER PATIENTS WITH POSITIVE PELVIC LYMPH NODES AND IS ASSOCIATED WITH A SURVIVAL BENEFIT AFTER ADJUVANT CHEMOTHERAPY: A MULTI-INSTITUTIONAL STUDY Pranav Sharma, Rosa Djajadiningrat, Kamran Zargar-Shoshtari, Mario Catanzaro, Yao Zhu, Nicola Nicolai, Simon Horenblas, and Philippe Spiess Pranav SharmaPranav Sharma More articles by this author , Rosa DjajadiningratRosa Djajadiningrat More articles by this author , Kamran Zargar-ShoshtariKamran Zargar-Shoshtari More articles by this author , Mario CatanzaroMario Catanzaro More articles by this author , Yao ZhuYao Zhu More articles by this author , Nicola NicolaiNicola Nicolai More articles by this author , Simon HorenblasSimon Horenblas More articles by this author , and Philippe SpiessPhilippe Spiess More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.412AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Although penile cancer patients with positive pelvic lymph nodes (PPLN) have a poor prognosis, the natural history, recurrence patterns, risk factors of survival, and impact of adjuvant therapy are not well understood. Using multi-institutional data across four tertiary referral centers, we aimed to clarify the answers to these questions. METHODS We identified 141 patients from 1978 to 2014 with PPLN after pelvic lymph node dissection (PLND) for metastatic squamous cell carcinoma (SCC) of the penis. Relevant clinical and pathological characteristics were identified and recorded via retrospective chart review, and vital status was noted from the time of PLND until last follow-up or date of death. Multivariate Cox regression was performed to evaluate the association of these variables with overall survival (OS), which was estimated using the Kaplan-Meier method. Differences in OS between relevant subgroups was determined with the log-rank test. RESULTS Median number of positive inguinal LN in our patient population was 4 (interquartile range [IQR]: 2 – 5) with 58.9% of cases occurring bilaterally in the groin and 78.7% having inguinal extranodal extension (ENE). Median number of PPLN was 2 (IQR: 1 – 4) with 55.8% of cases having pelvic ENE. Neoadjuvant chemotherapy was used in 27.0% of patients, adjuvant radiation therapy (XRT) in 39.0%, adjuvant chemotherapy in 27.7%, and salvage chemotherapy in 13.5%. Disease progression was seen in 12.8% of patients while disease recurrence was seen in 58.2% of patients. Of those recurrences, 48.8% occurred distantly, 46.3% occurred regionally in the groin or pelvis, and 4.9% occurred locally in the penile bed. Median OS in our patient population was 13.3 months (IQR: 6.9 – 33.1). ENE in the pelvic LNs was independently associated with worse OS (hazard ratio [HR]: 1.622; 95% confidence interval [CI]: 1.029-2.557; p=0.037) with a median OS of 11.1 months (IQR: 5.2 – 26.6) vs 15.4 (IQR: 9.2 – 104) in patients without pelvic ENE. Use of adjuvant chemotherapy improved OS in pelvic ENE positive patients (20.7 vs 8.0 months; p=0.001) but was not as effective in pelvic ENE negative patients (21.7 vs 14.4 months; p=0.207). CONCLUSIONS Penile cancer patients with PPLN have a significant mortality risk and a high distant recurrence rate. Pelvic ENE is a poor prognostic factor that impacts survival, but use of adjuvant chemotherapy can be associated with improved outcomes. Prospective studies are needed to further investigate these findings. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e115 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Pranav Sharma More articles by this author Rosa Djajadiningrat More articles by this author Kamran Zargar-Shoshtari More articles by this author Mario Catanzaro More articles by this author Yao Zhu More articles by this author Nicola Nicolai More articles by this author Simon Horenblas More articles by this author Philippe Spiess More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...